Anticoagulation in hospitalized patients with COVID-19
Lisa Baumann Kreuziger, Michelle Sholzberg, Mary Cushman
Abstract
Coronavirus disease-19 (COVID-19) includes a thromboinflammatory syndrome that may manifest with microvascular and macrovascular thrombosis. Patients with COVID-19 have a higher incidence of venous thromboembolism than other hospitalized patients. Three randomized control trials suggesting benefit of therapeutic heparin in hospitalized noncritically ill patients with COVID-19 have led to conditional guideline recommendations for this treatment. By contrast, prophylactic-dose heparin is recommended for critically ill patients. Unprecedented collaboration and rapidly funded research have improved care of hospitalized patients with COVID-19.
Topics & Concepts
MedicineCoronavirus disease 2019 (COVID-19)Intensive care medicineHeparinGuidelineIncidence (geometry)Randomized controlled trial2019-20 coronavirus outbreakThrombosisVenous thrombosisSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Internal medicineDiseaseInfectious disease (medical specialty)OutbreakVirologyPathologyOpticsPhysicsVenous Thromboembolism Diagnosis and ManagementCOVID-19 Clinical Research StudiesLong-Term Effects of COVID-19